Active substanceSildenafilSildenafil
Similar drugsTo uncover
  • Viagra®
    pills inwards 
    Pfizer Inc.     USA
  • Viagra®
    pills inwards 
    Pfizer Inc.     USA
  • Viassan-LF
    pills inwards 
    LEKFARM, SOOO     Republic of Belarus
  • Viathine
    pills inwards 
  • VIVAYRA®
    pills inwards 
  • Vizarsin®
    pills inwards 
  • Vizarsin® Ku-tab®
    pills inwards 
  • Wilderegra
    pills inwards 
    ATOLL, LLC     Russia
  • Dynamics
    pills inwards 
  • Dynamic Forward
    films inwards 
  • Invida ODP
    films inwards 
  • Maxigra
    pills inwards 
  • Olmax Strong
    pills inwards 
    AKTAVIS GROUP, AO     Iceland
  • Revacio®
    pills inwards 
    Pfizer Inc.     USA
  • Rijamp
    pills n / az. 
  • Silafil
    pills inwards 
    Hemofarm AD     Serbia
  • Silden®
    pills inwards 
    Sopharma, AO     Bulgaria
  • Sildenafil
    pills inwards 
  • Sildenafil
    pills inwards 
    FARMAKTIV, LLC     Russia
  • Sildenafil
    pills inwards 
    VERTEKS, AO     Russia
  • Sildenafil VERTEX
    pills inwards 
    VERTEKS, AO     Russia
  • Sildenafil Cardio
    pills inwards 
    NORTH STAR, CJSC     Russia
  • Sildenafil SZ
    pills inwards 
    NORTH STAR, CJSC     Russia
  • Taxiere®
    pills inwards 
    Zentiva as.     Czech Republic
  • Tornetis®
    pills inwards 
    Sandoz d.     Slovenia
  • Erexel®
    pills inwards 
       
  • EFFEX® Sildenafil
    pills inwards 
    EVALAR, CJSC     Russia
  • Dosage form: & nbspfilm coated tablets
    Composition:
    One tablet, film-coated, contains:
    Dosage of 25 mg
    active substance: sildenafil citrate (in terms of sildenafil) - 25.00 mg; additives: lactose monohydrate - 72.89 mg, microcrystalline cellulose - 30.00 mg, croscarmellose sodium - 7.50 mg, giprolose (hydroxypropyl cellulose) - 1.50 mg, silicon colloidal dioxide - 1.50 mg, magnesium stearate - 1 , 50 mg;
    film coating, [dry film-coating mixture containing polyvinyl alcohol (40%), titanium dioxide (22.1%), macrogol 3350 (polyethylene glycol 3350) (20.2%), talc (14.8%), lacquer aluminum based on indigo carmine dye (2.8%), iron oxide yellow (iron oxide) (0.1%)] - 4.50 mg.
    Dosage 50 mg
    active substance: sildenafil citrate (in terms of sildenafil) - 50.00 mg; auxiliary substances: lactose monohydrate 145.77 mg, microcrystalline cellulose 60.00 mg,croscarmellose sodium - 15.00 mg, giprolose (hydroxypropyl cellulose) - 3.00 mg, silicon dioxide colloid - 3.00 mg, magnesium stearate - 3.00 mg; film coating: [dry film-coating mixture containing polyvinyl alcohol (40%), titanium dioxide (22.1%), macrogol 3350 (polyethylene glycol 3350) (20.2%), talc (14.8%), aluminum lacquer based on indigo carmine dye (2.8%), iron oxide yellow (iron oxide) (0.1%)] - 9.00 mg.
    Dosage of 100 mg
    active substance: sildenafil citrate (in terms of sildenafil) - 100.00 mg; additives: lactose monohydrate 291.55 mg, microcrystalline cellulose 120.00 mg, croscarmellose sodium 30.00 mg, giprolose hydroxypropyl cellulose 6.00 mg, silicon colloidal dioxide 6.00 mg, magnesium stearate 6 , 00 mg; film coating: [dry film-coating mixture containing polyvinyl alcohol (40%), titanium dioxide (22.1%), macrogol 3350 (polyethylene glycol 3350) (20.2%), talc (14.8%), aluminum lacquer based on indigo carmine dye (2.8%), iron oxide yellow (iron oxide) (0.1%)] - 18.00 mg.

    Description:
    Round biconvex tablets, covered with a film coating of blue color. On the cross section, the nucleus is white or almost white in color.

    Pharmacotherapeutic group:Erectile dysfunction medication is a PDE5-inhibitor.
    ATX: & nbsp

    G.04.B.E   Drugs for the treatment of erectile dysfunction

    G.04.B.E.03   Sildenafil

    Pharmacodynamics:
    Sildenafil is a potent selective inhibitor of cyclo-guanosine monophosphate (cGMP) - a specific type 5 phosphodiesterase (PDE5). Restores impaired erectile function by increasing the flow of blood to the penis.
    The realization of the physiological mechanism of erection is associated with the release of nitric oxide (N0) in the cavernous body during sexual stimulation. This, in turn, leads to an increase in the level of cGMP, subsequent relaxation of the smooth muscle tissue of the cavernous body and an increase in blood flow.
    Sildenafil does not have a direct relaxing effect on an isolated cavernous human body, but enhances the effect of nitric oxide (N0) by inhibiting PDE5, which is responsible for the degradation of cGMP.
    When NO / cGMP is activated, which occurs under the influence of sexual stimuli, suppression of PDE5 with sildenafil leads to an increase in cGMP in the cavernous body. Thus, sexual stimulation is necessary to develop the desired pharmacological action of sildenafil.
    Sildenafil is selective for PDE5 in vitro, its activity against PDE5 is higher than that of other known isoenzymes of phosphodiesterase: PDE6 - 10-fold; FDE1 - more than 80 times; PDE2, PDE4, PDE7-PDE11 - more than 700 times. Sildenafil is 4000 times more selective for PDE5 than FDES, which is of paramount importance, since FDEZ is one of the key enzymes in the regulation of myocardial contractility.
    Sildenafil causes a small and transient decrease in blood pressure (BP), which in most cases has no clinical manifestations. The average maximum decrease in systolic blood pressure in the supine position after taking sildenafil inside at a dose of 100 mg is 8.3 mm Hg. Art. The corresponding change in diastolic blood pressure is 5.3 mm Hg. Art. A single oral intake of sildenafil in a dose of 100 mg was not accompanied by clinically significant changes in the electrocardiogram (ECG) in healthy volunteers. Sildenafil does not affect cardiac output and does not change blood flow through stenosed arteries. A more pronounced, but also transient, effect on blood pressure was noted in patients taking nitrates.
    In some patients, an easy and transient impairment in the ability to distinguish between shades of color (blue / green) was detected 1 hour after taking 100 mg of sildenafil with the Farnsworth-Munssel test 100. After 2 hours after taking the drug, these changes were absent. It is believed that the violation of color vision is caused by the inhibition of PDE6, which is involved in the transmission of light in the retina of the eye. Sildenafil does not affect visual acuity, perception of contrast, electroretinogram, intraocular pressure or the diameter of the pupil.

    Pharmacokinetics:
    The pharmacokinetics of sildenafil in the recommended dose range is linear. Suction
    Sildenafil is rapidly absorbed after ingestion. Absolute bioavailability averages about 40% (from 25% to 63%). In vitro sildenafil at a concentration of about 1.7 ng / ml (3.5 nM), suppresses the activity of the human PDE5 by 50%. After a single intake of sildenafil in a dose of 100 mg, the average maximum concentration of free sildenafil in the blood plasma (Cmax) of men is about 18 ng / ml (38 nM). Cmax when taking sildenafil inside fasting is achieved on average for 60 minutes (from 30 minutes to 120 minutes).When taken in combination with fatty foods, the suction rate decreases: Cmax decreases by an average of 29%, and the time to reach the maximum concentration (Tmax) increases by 60 min, but the degree of absorption does not change significantly (the area under the pharmacokinetic concentration-time curve (AUC) decreases on 11%).
    Distribution
    The volume of distribution of sildenafil in the equilibrium state averages 105 liters. The association of sildenafil and its main circulating N-demethyl metabolite with plasma proteins is about 96% and does not depend on the total drug concentration. Less than 0.0002% of the dose of sildenafil (an average of 188 ng) was found in the sperm 90 minutes after taking the drug.
    Metabolism
    Sildenafil is metabolized mainly in the liver under the action of the cytochrome CYP3A4 isoenzyme (the main pathway) and the cytochrome isoenzyme CYP2C9 (an additional pathway). The main circulating active metabolite, formed as a result of N-demethylation of sildenafil, undergoes further metabolism. The selectivity of this metabolite against PDE is comparable to that of sildenafil, and its activity in relation to PDE5 in vitro is about 50% of the activity of sildenafil. The concentration of the metabolite in the blood plasma of healthy volunteers was about 40% of the concentration of sildenafil.N-demethyl metabolite undergoes further metabolism; its half-life (Tm) is about 4 hours.
    Excretion
    The total clearance of sildenafil is 41 liters / hour, and the final Tsh is 3-5 hours. After oral administration sildenafil is excreted as metabolites, mainly by the intestine (about 80% of the dose) and to a lesser extent by the kidneys (about 13% of the dose).
    Pharmacokinetics in special patient groups
    In healthy elderly patients (over 65 years), the clearance of sildenafil is reduced, and the concentration of free sildenafil in blood plasma is approximately 40% higher than in young (18-45 years). Age does not have a clinically significant effect on the incidence of side effects. Patients with impaired renal function
    In mild (creatinine clearance 50 to 80 ml / min) and moderate (KK 30-49 ml / min) degree of renal insufficiency, the pharmacokinetics of sildenafil after single ingestion at a dose of 50 mg does not change. In severe renal failure (CK <30 ml / min), the clearance of sildenafil decreases, which leads to approximately a two-fold increase in AUC (100%) and Cmax (88%), compared with those for normal kidney function in patients of the same age group.
    Patients with impaired hepatic function
    In patients with cirrhosis of the liver (stages A and B according to the Child-Pugh classification), the clearance of sildenafil decreases, which leads to an increase in AUC (84%) and Cmax (47%), compared with those for normal liver function in patients of the same age group. The pharmacokinetics of sildenafil in patients with severe impairment of liver function (Stage C according to the Child-Pugh classification) has not been studied.

    Indications:
    Treatment of erectile dysfunction characterized by an inability to achieve or maintain an erection penis sufficient for a satisfactory sexual intercourse. Effective only with sexual stimulation.

    Contraindications:
    • hypersensitivity to sildenafil or to any other component of the drug;
    • use in patients receiving continuous or intermittent donators of nitric oxide, organic nitrates or nitrites in any form, since sildenafil strengthens the hypotensive effect of nitrates (see section "Interaction with other drugs");
    • use in patients for whom sexual activity is undesirable (for example, with severe cardiovascular diseases, such as severe heart failure,unstable angina);
    • arterial hypotension (blood pressure less than 90/50 mm Hg);
    • a disorder of cerebral circulation or myocardial infarction suffered during the last six months;
    • hereditary degenerative diseases of the retina, including retinitis pigmentosa (a minority of these patients have a genetic disorder of retinal phosphodiesterase);
    • lactose intolerance, lactase deficiency, glucose-galactose malabsorption;
    • severe hepatic impairment;
    • simultaneous reception of ritonavir;
    • simultaneous reception of other drugs for the treatment of erectile dysfunction;
    • age to 18 years;
    • use of the drug in women.

    Carefully:
    • arterial hypertension (blood pressure> 170/100 mm Hg);
    • life-threatening arrhythmias;
    • obstructive diseases of the inferior part of the left ventricle of the heart (aortic stenosis, hypertrophic obstructive cardiomyopathy);
    • anatomical deformation of the penis (angulation, cavernous fibrosis or Peyronie's disease);
    • patients with episodes of development of anterior non-artery ischemic neuropathy of the optic nerve in anamnesis;
    • diseases predisposing to the development of priapism (sickle cell anemia, multiple myeloma, leukemia, thrombocythemia); diseases accompanied by bleeding;
    • peptic ulcer in the stage of exacerbation;
    • simultaneous administration of alpha-blockers.

    Pregnancy and lactation:
    According to the registered indication the drug is not intended for use in women.

    Dosing and Administration:
    Inside.
    The recommended dose for most adult patients is 50 mg about 1 hour before sexual activity.
    With regard to efficacy and tolerability, the dose can be increased to 100 mg or reduced to 25 mg. The maximum recommended dose is 100 mg. The maximum recommended frequency of application is once a day.
    At a mild and moderate degree of renal failure (CK 30-80 ml / min) dose adjustment is not required, in severe renal failure (CK <30 ml / min), the dose of sildenafil should be reduced to 25 mg.
    Since the excretion of sildenafil is disrupted in patients with liver damage (in particular, with cirrhosis), the dose of sildenafil should be reduced to 25 mg.
    Correction of the dose of sildenafil in elderly patients is not required.
    When combined with cytochrome CYP3A4 isoenzyme inhibitors (erythromycin, saquinavir, ketoconazole, itraconazole), the initial dose of sildenafil should be 25 mg (see section "Interaction with other drugs").
    To minimize the risk of postural hypotension in patients taking alpha-blockers, the use of sildenafil should be started only after hemodynamic stabilization has been achieved in these patients. The initial dose of sildenafil is 25 mg (see sections "Special instructions" and "Interaction with other drugs").

    Side effects:
    Classification of the incidence of adverse events (WHO):
    very often> 1/10;
    often from > 1/100 to <1/10;
    infrequently from> 1/1000 to <1/100;
    rarely from > 1/10000 to <1/1000;
    very rarely <1/10000, including individual messages;
    frequency
    not
    frequency is unknown: according to available data, establish
    it is possible.
    From the nervous system:
    very often - headache;
    often - dizziness;
    infrequently - drowsiness, hypoesthesia;
    rarely - cerebrovascular events, fainting;
    frequency unknown - transient ischemic attack, convulsions, incl.recurrent.
    From the side of the organ of vision:
    often - visual impairment, transient disorders of color perception (chromatopsy); infrequently - a lesion of the conjunctiva, a violation of tear formation;
    frequency unknown - anterior ischemic optic neuropathy of non-arterial genesis, occlusion of retinal vessels, visual field defects.
    From the organ of hearing:
    infrequent - dizziness, noise in the ears;
    rarely - deafness.
    From the cardiovascular system:
    often - flushes of blood to the skin of the face;
    infrequent - a feeling of palpitations, tachycardia;
    rarely - increase or decrease in blood pressure, myocardial infarction, atrial fibrillation;
    frequency unknown - ventricular arrhythmia, unstable angina, sudden cardiac arrest.
    From the respiratory system: often - nasal congestion; rarely - epistaxis.
    From the gastrointestinal tract: often - dyspepsia;
    infrequently - vomiting, nausea, dryness of the oral mucosa.
    Allergic reactions: infrequent - skin rash;
    frequency unknown - Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell syndrome).
    From the musculoskeletal system: infrequently - myalgia.
    On the part of the genitals:
    infrequently - hematospermia, bleeding from the penis; frequency unknown - priapism, prolonged erection.
    Other-.
    infrequently - pain in the chest, increased fatigue.

    Overdose:
    Symptoms: headache, "tides" of blood to the skin, dizziness, dyspepsia, nasal congestion, blurred vision.
    In single dose of sildenafil at a dose of 800 mg of adverse events were comparable to those when taking the drug at a low dose, but were more common. Treatment ', symptomatic. Hemodialysis does not accelerate the clearance of sildenafil, since the latter actively binds to plasma proteins and is not excreted by the kidneys.

    Interaction:
    The effect of other drugs on the pharmacokinetics Sildenafil Sildenafil metabolism occurs primarily in the liver under the influence of isoenzyme cytochrome CYP3A4 (major route) and CYP2C9, so inhibitors of these isozymes may reduce the clearance of sildenafil and inductors, respectively, to increase the clearance of sildenafil. A decrease in the clearance of sildenafil with simultaneous application of inhibitors of the cytochrome isoenzyme CYP3A4 (ketoconazole, erythromycin, cimetidine). Cimetidine (800 mg), a non-specific inhibitor of the cytochrome isoenzyme CYP3A4, when co-administered with sildenafil (50 mg) causes an increase in the concentration of sildenafil in plasma by 56%.
    A single dose of 100 mg of sildenafil together with erythromycin (500 mg / day twice a day for 5 days), a specific inhibitor of the cytochrome CYP3A4 isoenzyme, with the achievement of a constant concentration of erythromycin in the blood, increases the sildenafil AUC by 182%.
    With the simultaneous administration of sildenafil (once 100 mg) and saquinavir (1200 mg / day 3 times a day), the HIV protease inhibitor and the cytochrome CYP3A4 isoenzyme, while achieving a constant saquinavir concentration in the blood, Cmax sildenafil increased by 140%, and the AUC increased by 210%. Sildenafil does not affect the pharmacokinetics of saquinavir. More potent cytochrome CYP3A4 isoenzyme inhibitors, such as ketoconazole and itraconazole, can cause and stronger changes in the pharmacokinetics of sildenafil. Simultaneous use of sildenafil (once 100 mg) and ritonavir (500 mg twice a day), an HIV protease inhibitor and a strong inhibitor of cytochrome P450, with the achievement of a constant concentration of ritonavir in the blood leads to an increase in Cmax sildenafil by 300% (4-fold ), and AUC - by 1000% (11 times).After 24 hours, the concentration of sildenafil in the blood plasma is about 200 ng / ml (after a single application of one sildenafil - 5 ng / ml).
    Grapefruit juice, a weak inhibitor of CYP3A4, may moderately increase the plasma concentration of sildenafil.
    If sildenafil take in recommended doses of patients receiving simultaneously strong inhibitors of the cytochrome isoenzyme CYP3A4, then Cmax of free sildenafil does not exceed 200 nM, and the drug is well tolerated.
    A single dose of antacid (hydroxide / magnesium hydroxide, aluminum) did not affect the bioavailability of sildenafil.
    Inhibitors of the cytochrome isoenzyme CYP2C9 (such as tolbutamide, warfarin), cytochrome CYP2D6 isoenzyme (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and thiazide-like diuretics, ACE inhibitors (angiotensin converting enzyme), and calcium antagonists have no effect on the pharmacokinetic parameters of sildenafil.
    Azithromycin (500 mg / day for 3 days) does not affect AUC, Cmax, Tmax, rate of elimination rate and T1 / 2 sildenafil or its main circulating metabolite. Nicorandil is a hybrid of nitrate and potassium channel activator. Due to the presence of a nitrate component, it can enter into serious interactions with sildenafil. Effect of sildenafil on other drugs
    Sildenafil is a weak inhibitor of cytochrome P450 - 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 isoenzymes (HKso> 150 μmol). When taking sildenafil in the recommended doses of it
    Cmax is about 1 μmol, so it is unlikely that sildenafil can affect the clearance of the substrates of these isoenzymes.
    Sildenafil enhances the hypotensive effect of nitrates both with prolonged use of the latter, and when they are prescribed for acute indications. In this regard, the use of sildenafil in combination with nitrates or donators of nitric oxide is contraindicated.
    With simultaneous administration of alpha-adrenoblocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg and 100 mg) in patients with benign prostatic hyperplasia with stable hemodynamics, the mean additional decrease in systolic / diastolic blood pressure in the supine position was 7/7 mm Hg. st., 9/5 mm Hg. Art. and 8/4 mm Hg. Art. respectively, while in the standing position it is 6/6 mm Hg.st., 11/4 mm Hg. Art. and 4/5 mm Hg. Art. respectively. We report rare cases of development in these patients of symptomatic postural hypotension, manifested as dizziness (without syncope). In individual sensitive patients receiving alpha-blockers, simultaneous use of sildenafil can lead to symptomatic hypotension. Signs of significant interaction of sildenafil (50 mg) with tolbutamide (250 mg) or warfarin (40 mg), which are metabolized by the isoenzyme of cytochrome CYP2C9, have not been identified.
    Sildenafil (100 mg) does not affect the pharmacokinetics of HIV protease, saquinavir and ritonavir inhibitors, which are substrates of the cytochrome CYP3A4 isoenzyme, at their constant level in the blood.
    Sildenafil (50 mg) does not cause an additional increase in bleeding time when taking acetylsalicylic acid (150 mg).
    Sildenafil (50 mg) does not increase the hypotensive effect of ethanol in healthy volunteers with a maximum concentration of ethanol in the blood averaging 0.08% (80 mg / dL).
    In patients with hypertension, there was no evidence of interaction between sildenafil (100 mg) and amlodipine.The average additional decrease in blood pressure in the prone position is 8 mm Hg. Art. (systolic) and 7 mm Hg. Art. (diastolic).
    The use of sildenafil in combination with antihypertensive drugs does not lead to additional side effects.

    Special instructions:
    To diagnose erectile dysfunction, determine their possible causes and choose an adequate treatment, you must collect a complete medical history and conduct a thorough physical examination. Means the treatment of erectile dysfunction should be used with caution in patients with anatomical deformation of the penis (penile angulation, cavernous fibrosis, Peyronie's disease) or in patients with risk factors for development of priapism (sickle-cell anemia, multiple myeloma, leukemia). Drugs intended for the treatment of erectile dysfunction should not be prescribed to men for whom sexual activity is undesirable.
    Sexual activity represents a certain risk in the presence of heart disease, so before starting any therapy for erectile dysfunction, the doctor should refer the patient to a cardiovascular system examination.The use of sildenafil is contraindicated in patients with heart failure, unstable angina, pasture for the last six months myocardial infarction or stroke, hypotension (BP <90/50 mm Hg). In clinical studies, there was no difference in the incidence of myocardial infarction (1.1 per 100 people per year) or mortality from cardiovascular disease (0.3 per 100 people per year) in patients who received sildenafil, compared with patients receiving placebo.
    Cardiovascular complications
    In the postmarketing use of sildenafil, serious adverse events such as myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, hemorrhagic stroke, transient ischemic attack, severe cardiovascular complications,
    hypertension and hypotension), which had a temporary connection with the use of sildenafil. Most of these patients, but not all of them, had risk factors for cardiovascular complications. Many of these adverse events were observed soon after sexual activity and some of them were noted after taking sildenafil without subsequent sexual activity.It is not possible to establish the presence of a direct link between the observed undesirable phenomena and the indicated factors.
    Hypotension
    Sildenafil has a systemic vasodilating effect, resulting in a transient decrease in blood pressure, which is not clinically significant and does not lead to any consequences in most patients. Nevertheless, before the appointment of sildenafil, the physician should carefully evaluate the risk of possible undesirable manifestations of vasodilating action in patients with the corresponding diseases, especially against the background of sexual activity. Increased susceptibility to vasodilators is observed in patients with obstruction of the left ventricular outflow tract (aortic stenosis, hypertrophic obstructive cardiomyopathy), as well as with a rare syndrome of multiple systemic atrophy, manifested severe violation of the regulation of blood pressure from the autonomic nervous system.
    Since the combined use of sildenafil and alpha-blockers can lead to symptomatic hypotension in selected sensitive patients, sildenafil should be administered with caution to patients taking alpha-blockers (see.section "Interaction with other drugs"). To minimize the risk of postural hypotension in patients taking alpha-adrenoblockers, the use of sildenafil should be started only after the stabilization of hemodynamics in these patients has been achieved. It should also consider the desirability of reducing the initial dose of sildenafil (see section "Method of administration and dose"). The doctor should inform the patient about what actions should be taken in case of symptoms of postural hypotension.
    Some post-marketing and clinical studies report cases of sudden deterioration or hearing loss associated with the use of all PDE5 inhibitors, including sildenafil. However, in most cases, these patients had risk factors for the development of this pathology. The causal relationship between the use of PDE5 inhibitors and sudden deterioration of hearing or loss of hearing is not established. The patient should be warned that in the event of a sudden decrease or sudden loss of hearing, stop sildenafil therapy and consult a doctor immediately. Sildenafil enhances the antiplatelet effect of sodium nitroprusside (a donor of nitric oxide) on human platelets in vitro. Data on the safety of sildenafil in patients with a tendency to bleeding or exacerbation of peptic ulcer of the stomach and duodenum are absent, therefore sildenafil these patients should be used with caution (see "With caution").
    The safety and effectiveness of the use of sildenafil in conjunction with other treatments for erectile dysfunction have not been studied, so the use of such combinations is not recommended.

    Effect on the ability to drive transp. cf. and fur:Since the use of sildenafil may reduce blood pressure, the development of chromatopsy, blurred vision, etc. side effects, you should carefully consider the individual effect of the drug in these situations, especially at the beginning of treatment and when changing the dosage regimen.
    Form release / dosage:
    Film coated tablets, 25 mg, 50 mg and 100 mg.
    1, 2, 3, 4, 5, 6 or 10 tablets in a planar cell packaging made of a polyvinylchloride film and aluminum foil.
    10 tablets in a can of high-density polyethylene.
    1 or 2 contour packs of 1 tablet, 1 or 2 contour packs of 2 tablets, 4 contiguous packs of cells for 3 tablets, 1, 2, 3 or 5 contour cell packs of 4 tablets, 2 or 4 contour packs of 5 tablets,
    2 contour packs of 6 tablets, 1 or 2 contour packs of 10 tablets or one can, together with instructions for medical use in a pack of cardboard.

    Packaging:
    1, 2, 3, 4, 5, 6 or 10 tablets in a planar cell packaging made of a polyvinylchloride film and aluminum foil.
    10 tablets in a can of high-density polyethylene.
    1 or 2 contour packs of 1 tablet, 1 or 2 contour packs of 2 tablets, 4 contiguous packs of cells for 3 tablets, 1, 2, 3 or 5 contour cell packs of 4 tablets, 2 or 4 contour packs of 5 tablets,
    2 contour packs of 6 tablets, 1 or 2 contour packs of 10 tablets or one can, together with instructions for medical use in a pack of cardboard.
    Storage conditions:
    In the dark place at a temperature of no higher than 25 ° C.
    Keep out of the reach of children.

    Shelf life:
    3 of the year.
    Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-002593
    Date of registration:20.08.2014
    The owner of the registration certificate:VERTEKS, AO VERTEKS, AO Russia
    Manufacturer: & nbsp
    Representation: & nbspVERTEKS CJSC VERTEKS CJSC Russia
    Information update date: & nbsp20.08.2014
    Illustrated instructions
      Instructions
      Up